Recent meta-analyses and GWAS have shown a fivefold increased risk, similar to that of APOE-ε4 carriers, of developing EOAD with rare variants in SORL1 (Ayodele et al., 2021) and a study that used the Exome Aggregation Consortium (ExAC; ExAC browser is not available anymore, and it is now part of the gnomAD) database established that pathogenic SORL1 variants increase AD risk by 12-fold, as well as causing an earlier age of onset (58.6 ± 5.2 years) (Holstege et al., 2017). Here, APOE is linked to Alzheimer disease.